Company intelligence / Profile preview

Optithera

Ownership: Private
Development stage: Other

Overview

Optithera has developed and clinically validated a saliva-based polygenic risk score test that predicts the likelihood of developing kidney, heart, and cerebrovascular complications in patients with type 2 diabetes. The test has been validated in over 20,000 patients from more than 20 countries and shown to improve patient stratification for intensive treatment. Clinical studies demonstrated significant reductions in cardiovascular mortality among high-risk groups identified by the test[4]. The technology is supported by public-private partnerships and funding from Genome Canada.

Therapeutic areas: Endocrinology
Modalities: Genetic testPolygenic risk score (as a diagnostic tool, not a therapeutic)
Industry: Molecular Diagnostics

Partnerships

Genome Canada (funding/support)

Beyond the preview

Go deeper on Optithera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optithera.

Explore the full profile